Apeximmune Therapeutics
California, United States · Biotechnology, Health Care, Therapeutics · 7 employees
Apeximmune Therapeutics is a biotechnology company focused on developing next-generation immunotherapies for cancer and autoimmune diseases. By leveraging cutting-edge science and a deep understanding of immune mechanisms, the company aims to deliver transformative treatments that improve patient outcomes.
Funding history
- Series series a — $21.3M — Apr 2025
Recent signals
- Apr 01, 2025: Raised $21.3M in Series series a
See plans & pricing → Track Apeximmune Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.